Related Experiment Video
Updated: Apr 29, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Treatment strategies for myeloid growth factors and intravenous iron: when, what, and how?
Jeffrey Crawford1, George M Rodgers1
1Presented by Jeffrey Crawford, MD, Chief, Division of Medical Oncology, Professor of Medicine, Duke Cancer Institute, Durham, North Carolina, and George M. Rodgers, MD, PhD, Professor of Medicine, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah.
Abstract:
Myeloid growth factors can reduce the risk of chemotherapy-induced neutropenia (CIN) and thus impact the survival of patients with cancer. Patients should be assessed for risk, taking into consideration patient-related risk factors and chemotherapy regimens. Patients stratified as having at least a 20% risk for CIN should be considered for prophylactic growth factors. The NCCN Guidelines for Myeloid Growth Factors provide category 1 recommendations for the daily use of filgrastim, tbo-filgrastim, and pegfilgrastim. Cancer-related anemia can be treated with erythropoiesis-stimulating agents, red blood cell transfusion, or intravenous iron.
Related Concept Videos
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Venous Thrombosis III: Interprofessional Care
Regulation of Hematopoietic Stem Cells
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Heart Failure VI: Adjunct Therapies
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

